Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
The diagnosis, treatment, and monitoring of the primary systemic vasculitides associated with circulating antineutrophil cytoplasm autoantibodies (ANCA) have formed the focus of a multicenter collaborative study. Consensus has been reached on criteria for classification, clinical subgroupings by ext...
Principais autores: | Jayne, DR, Rasmussen, N |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
1997
|
Registros relacionados
-
Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
por: Mukhtyar, C, et al.
Publicado em: (2006) -
Comments on: Antineutrophil cytoplasmic autoantibody associated vasculitis-Clinical profile and outcomes
por: Rohini Handa
Publicado em: (2018-01-01) -
Ischaemic stroke as the first presentation of antineutrophilic cytoplasmic autoantibody‐associated vasculitis
por: John Chuan Nguyen Tran, et al.
Publicado em: (2022-12-01) -
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
por: Flossmann, O, et al.
Publicado em: (2006) -
Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Kidney Involvement in a Patient with AL Amyloidosis
por: Brendan L. Thoms, et al.
Publicado em: (2021-07-01)